GHK-Cu: topical vs injection
Topical GHK-Cu and injectable GHK-Cu are different routes, not interchangeable evidence. An August 2026 aesthetic-medicine review included 20 studies, of which 18 were preclinical and two were randomised trials. FDA’s separate safety entry specifically addresses injectable GHK-Cu preparations.
Read the route with the claim
Swipe or scroll sideways to compare all columns.
| Question | Topical / skin delivery | Injection |
|---|---|---|
| What to identify | Formulation and skin-delivery method | Exact injectable formulation and route |
| Relevant evidence here | Aesthetic review: limited clinical studies among preclinical work | FDA injectable GHK-Cu safety note |
| What cannot be assumed | That a cosmetic finding supports an injection | That a topical formulation establishes injectable safety |
What the new review adds
The review describes findings on wrinkle measures and satisfaction after laser resurfacing, but also methodological variation and few well-designed clinical trials. Its study count is not a count of 20 successful human trials. The authors call for larger controlled studies and standardised formulations and delivery methods.
What FDA flags for injections
FDA describes possible immunogenicity from aggregation and peptide-related impurities, with limited human data to assess safety. This route-specific note should not be collapsed into either “all copper peptides are dangerous” or “skin-care use proves injections are safe.”
Use the table and its sources
Related reading
Source-linked editorial synthesis, prepared with AI assistance. This is not a clinician review or a personalised treatment recommendation. Corrections: editorial standards.